Abstract:Importance: Brand-name combination drugs can be more expensive than the sum of their components, especially when the constituent products are available as generic medications. The potential savings that could be achieved using generic components is not known.Objective: To estimate the additional cost to Medicare of prescribing brand-name combination medications instead of generic constituents.Design, Setting, and Participants: Retrospective analysis for 2011 through 2016 using the Medicare data set of Part D beneficiaries prescribed any of the 1500 medications that accounted for the highest total spending in 2015. Brand-name combination drugs that had identical or therapeutically equivalent generic constituents were included.Exposures: Brand-name, oral combination medications with constituents available either as generic drugs or therapeutically equivalent generic substitutes.Main Outcomes and Measures: The estimated difference between the amount spent by Medicare on brand-name combination drugs and the estimated amount that would have been spent on substitutable generic components.Results: Among the 1500 medications evaluated, 29 brand-name combination medications were separated into 3 mutually exclusive categories: constituents available as generic medications at identical doses (n = 20), generic constituents at different doses (n = 3), and therapeutically equivalent generic substitutes (n = 6). For the constituents available as generic medications at identical doses category, total spending by Medicare in 2016 on the brand-name combination products was $303 million and the estimated spending for the generic constituents would have been $68 million, which is an estimated difference of $235 million. For the generic constituents at different doses category, total spending by Medicare in 2016 on the brand-name combination products was $232 million and the estimated spending for the generic constituents would have been $13 million, which is an estimated difference of $219 million. For the therapeutically equivalent generic substitutes category, total spending by Medicare in 2016 on the brand-name combination products was $491 million and the estimated spending for the generic constituents would have been $20 million, which is an estimated difference of $471 million. In 2016, the estimated spending for the generic constituents for these 29 drugs would have been $925 million less than the estimated spending for the brand-name combinations. For the 10 most costly combination products available during the entire study period, the listed Medicare spending could have been an estimated $2.7 billion lower between 2011 and 2016 if the generic constituents had been prescribed.Conclusions and Relevance: In 2016, the difference between the amount that the Medicare drug benefit program reported spending on brand-name combination medications and the estimated spending for generic constituents for the same number of doses was $925 million. Promoting generic substitution and therapeutic interchange through prescriber education and more rational substitution policies may offer important opportunities to achieve substantial savings in the Medicare drug benefit program.

Estimating Rebates and Other Discounts Received by Medicare Part D

Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019

The Influence of Medicare Part D on the List Pricing of Brand Drugs

Variation in generic dispensing rates in Medicare Part D

Medicare Part D Protected-Class Policy Is Associated With Lower Drug Rebates

Spending on and Use of Clinician-Administered Drugs in Medicare

Potential impact of pharmacist interventions to reduce cost for Medicare Part D beneficiaries

Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents

Drug Pricing Stewardship from Mark Cuban's Cost Plus Generic Drug Program

Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025

Estimated Savings Under the Medicare High-Value Drug List Model

Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act

Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and Use

Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage

Potential Medicare Part D Savings on Ophthalmic Generic Drugs

Affordability and adherence gains for Medicare Part D low-income subsidy recipients when low-income subsidy benefits expanded in 2024

Unraveling Medicare and Medicaid Prescription Drug Fraud and Abuse

Assessing clinical benefit in the Medicare Drug Price Negotiation Program: A 2-step approach for improving transparency, consistency, and meaningful patient engagement

Medicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017

The impact of 1990 Medicaid drug rebates policy on access to prescriptions

Trends in the level and composition of supplemental benefits in Medicare Advantage